X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5166) 5166
Publication (505) 505
Book Review (126) 126
Book Chapter (33) 33
Conference Proceeding (19) 19
Book / eBook (10) 10
Web Resource (9) 9
Dissertation (6) 6
Magazine Article (6) 6
Government Document (2) 2
Presentation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4584) 4584
female (4111) 4111
breast neoplasms - drug therapy (2943) 2943
index medicus (2433) 2433
aromatase inhibitors (2281) 2281
aromatase inhibitors - therapeutic use (2241) 2241
oncology (2178) 2178
breast cancer (2092) 2092
postmenopausal women (1668) 1668
tamoxifen (1522) 1522
antineoplastic agents, hormonal - therapeutic use (1416) 1416
middle aged (1369) 1369
tamoxifen - therapeutic use (1195) 1195
aged (1150) 1150
triazoles - therapeutic use (1092) 1092
nitriles - therapeutic use (1090) 1090
breast neoplasms - pathology (993) 993
letrozole (940) 940
cancer (925) 925
postmenopause (874) 874
adult (873) 873
anastrozole (852) 852
estrogen (804) 804
endocrine therapy (793) 793
aromatase inhibitor (787) 787
treatment outcome (772) 772
antineoplastic agents - therapeutic use (754) 754
chemotherapy, adjuvant (737) 737
care and treatment (715) 715
randomized-trial (708) 708
aromatase (676) 676
animals (670) 670
aromatase inhibitors - adverse effects (622) 622
women (617) 617
breast neoplasms - metabolism (602) 602
obstetrics & gynecology (584) 584
male (536) 536
endocrinology & metabolism (526) 526
health aspects (493) 493
aged, 80 and over (478) 478
research (478) 478
enzyme inhibitors - therapeutic use (463) 463
therapy (459) 459
medicine & public health (450) 450
pharmacology & pharmacy (432) 432
antineoplastic combined chemotherapy protocols - therapeutic use (430) 430
receptors, estrogen - metabolism (428) 428
chemotherapy (426) 426
clinical trials as topic (403) 403
exemestane (399) 399
drug therapy (393) 393
androstadienes - therapeutic use (386) 386
risk factors (377) 377
neoplasms, hormone-dependent - drug therapy (373) 373
analysis (366) 366
double-blind (356) 356
antineoplastic agents, hormonal - adverse effects (346) 346
disease-free survival (337) 337
breast neoplasms - mortality (330) 330
randomized controlled trials as topic (326) 326
aromatase inhibitors - administration & dosage (325) 325
aromatase inhibitors - pharmacology (320) 320
estrogen antagonists - therapeutic use (315) 315
breast neoplasms - genetics (314) 314
adjuvant treatment (308) 308
expression (304) 304
article (301) 301
aromatase - metabolism (297) 297
prognosis (296) 296
megestrol-acetate (294) 294
first-line therapy (282) 282
selective estrogen receptor modulators - therapeutic use (281) 281
estrogen-receptor (279) 279
trial (278) 278
menopause (276) 276
hematology, oncology and palliative medicine (271) 271
neoplasm staging (269) 269
nitriles - adverse effects (268) 268
triazoles - adverse effects (268) 268
breast neoplasms - prevention & control (262) 262
triazoles - administration & dosage (262) 262
nitriles - administration & dosage (260) 260
breast neoplasms - surgery (257) 257
tamoxifen therapy (255) 255
prevention (252) 252
clinical trials (246) 246
tamoxifen - adverse effects (242) 242
biochemistry & molecular biology (241) 241
metastasis (241) 241
breast-cancer (236) 236
breast neoplasms - enzymology (229) 229
tamoxifen - administration & dosage (226) 226
estradiol - blood (225) 225
internal medicine (222) 222
phase-iii (222) 222
retrospective studies (221) 221
reproductive biology (220) 220
breast neoplasms - therapy (218) 218
estradiol (218) 218
pregnancy (217) 217
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4915) 4915
Japanese (77) 77
French (66) 66
German (45) 45
Italian (24) 24
Chinese (21) 21
Russian (16) 16
Spanish (15) 15
Hungarian (9) 9
Danish (8) 8
Dutch (5) 5
Czech (4) 4
Polish (4) 4
Bulgarian (3) 3
Romanian (3) 3
Finnish (2) 2
Hebrew (2) 2
Portuguese (2) 2
Swedish (2) 2
Bosnian (1) 1
Croatian (1) 1
Norwegian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 496 - 503
Summary In March, 2010, a group of breast cancer experts met to develop a consensus statement on breast cancer prevention, with a focus on medical and... 
Hematology, Oncology and Palliative Medicine | ZOLEDRONIC ACID | SURGICAL ADJUVANT BREAST | ONCOLOGY | STATIN USE | LOW-DOSE TAMOXIFEN | RANDOMIZED-TRIAL | FOLLOW-UP | RISK | BOWEL PROJECT | POSTMENOPAUSAL WOMEN | GENOME-WIDE ASSOCIATION | Thiophenes - therapeutic use | Metformin - therapeutic use | Raloxifene Hydrochloride - therapeutic use | Humans | Selective Estrogen Receptor Modulators - adverse effects | Tetrahydronaphthalenes - therapeutic use | Pyrrolidines - therapeutic use | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Estrogen Receptor Modulators - therapeutic use | Retinoids - therapeutic use | Selective Estrogen Receptor Modulators - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Female | Aromatase Inhibitors - therapeutic use | Estrogen Receptor Modulators - adverse effects | Anticarcinogenic Agents - therapeutic use | Triazoles - therapeutic use | Premenopause | Anastrozole | Consensus Development Conferences as Topic | Breast Neoplasms - prevention & control | Fenretinide - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Piperidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Tamoxifen - therapeutic use | Androstadienes - therapeutic use | Expert Testimony | Norpregnenes - therapeutic use | Nitriles - therapeutic use | COX-2 inhibitors | Care and treatment | Aspirin | Oncology, Experimental | Menopause | Phosphonates | Breast cancer | Retinoids | Research | Tamoxifen | Prevention | Analysis | Health aspects | Cancer
Journal Article
2008, 2nd rev. ed., Milestones in drug therapy, ISBN 3764386924, x, 189
Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the... 
Aromatase Inhibitors | drug therapy | Breast Neoplasms | therapeutic use | Clinical & internal medicine | Breast | Chemotherapy | Inhibitors | Aromatase | Therapeutic use | Cancer | Cancer Research | Oncology | Internal Medicine | Biomedicine | Pharmacology/Toxicology | Cell Biology
Book
2006, 1. Aufl., Milestones in drug therapy, ISBN 9783764374181, ix, 182
Book
by Dowsett, M and Forbes, J. F and Bradley, R and Ingle, J and Aihara, T and Bliss, J and Boccardo, F and Coates, A and Coombes, R. C and Cuzick, J and Dubsky, P and Gnant, M and Kaufmann, M and Kilburn, L and Perrone, F and Rea, D and Thurlimann, B and van de Velde, C and Pan, H and Peto, R and Davies, C and Gray, R and Burrett, J and Clarke, M and Duane, F and Evans, V and Gettins, L and Godwin, J and Liu, H and McGale, P and MacKinnon, E and McHugh, T and James, S and Morris, P and Read, S and Taylor, C and Wang, Y and Wang, Z and Bergh, J and Pritchard, K and Albain, K and Anderson, S and Arriagada, R and Barlow, W and Bergsten-Nordstrom, E and Buyse, M and Cameron, D and Coleman, R and Correa, C and Costantino, J and Davidson, N and Di Leo, A and Ewertz, M and Forbes, J and Gelber, R and Geyer, C and Gianni, L and Goldhirsch, A and Hayes, D and Hill, C and Janni, W and Martin, M and Norton, L and Ohashi, Y and Paik, S and Perez, E and Piccart, M and Pierce, L and Raina, V and Ravdin, P and Robertson, J and Rutgers, E and Sparano, J and Swain, S and Viale, G and von Minckwitz, G and Wang, X and Whelan, T and Wilcken, N and Winer, E and Wolmark, N and Wood, W and Abe, O and Abe, R and Enomoto, K and Kikuchi, K and Koyama, H and Masuda, H and Nomura, Y and Sakai, K and Sugimachi, K and Toi, M and Tominaga, T and Uchino, J and Yoshida, M and Haybittle, J. L and Leonard, C. F and Calais, G and Garaud, P and Collett, V and ... and Early Breast Canc Trialists and Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 10001, pp. 1341 - 1352
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 6, pp. 520 - 529
Resistance to hormone therapy through activation of cellular pathways involving mTOR can develop in postmenopausal hormone-receptor–positive breast cancer.... 
TRIAL | WOMEN | MEDICINE, GENERAL & INTERNAL | EFFICACY | TAMOXIFEN | PHASE-III | LETROZOLE | SUPERIOR | AROMATASE INHIBITORS | FIRST-LINE THERAPY | ANASTROZOLE | Recurrence | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bone Neoplasms - secondary | TOR Serine-Threonine Kinases - antagonists & inhibitors | Aromatase Inhibitors - adverse effects | Breast Neoplasms - chemistry | Aged, 80 and over | Postmenopause | Adult | Female | Aromatase Inhibitors - therapeutic use | Everolimus | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Kaplan-Meier Estimate | Receptor, Epidermal Growth Factor - analysis | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Stomatitis - chemically induced | Aged | Androstadienes - therapeutic use | Androstadienes - adverse effects | Drugs | Care and treatment | Usage | Hormone therapy | Patient outcomes | Drug utilization | Breast cancer | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | TOR protein | Anastrozole | Endocrine therapy | Fatigue | Intracellular signalling | Rapamycin | Tamoxifen | Cancer therapies | Survival | Post-menopause | Fulvestrant | Signal transduction | Stomatitis | Hyperglycemia | Chemotherapy | Pneumonitis | Dyspnea | Aromatase | Antitumor activity | Respiration
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2009, Volume 360, Issue 7, pp. 679 - 691
This large trial tested the effect of adding zoledronic acid to adjuvant endocrine treatment (goserelin plus tamoxifen or anastrozole) in premenopausal women... 
RECEIVING ADJUVANT LETROZOLE | MULTIPLE-MYELOMA | OVARIAN ABLATION | BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS | MEDICINE, GENERAL & INTERNAL | BONE LOSS | SOLID TUMORS | TAMOXIFEN | DELTA-T-CELLS | POSTMENOPAUSAL WOMEN | AUSTRIAN BREAST | Breast Neoplasms - surgery | Triazoles - adverse effects | Follow-Up Studies | Humans | Middle Aged | Receptors, Estrogen - analysis | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Imidazoles - therapeutic use | Drug Therapy, Combination | Goserelin - therapeutic use | Aromatase Inhibitors - therapeutic use | Diphosphonates - adverse effects | Triazoles - therapeutic use | Bone Density Conservation Agents - adverse effects | Premenopause | Imidazoles - adverse effects | Bone Density Conservation Agents - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Estrogen Antagonists - therapeutic use | Tamoxifen - therapeutic use | Estrogen Antagonists - adverse effects | Tamoxifen - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Zoledronic acid | Care and treatment | Usage | Breast cancer | Health aspects | Function tests (Medicine) | Chemotherapy | Acids | Womens health | Menopause | Colorectal cancer | Cytotoxicity | Radiation therapy | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article